These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 25434354)
1. KSP inhibitors as antimitotic agents. Pérez-Melero C Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354 [TBL] [Abstract][Full Text] [Related]
2. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP. Coleman PJ; Schreier JD; Cox CD; Fraley ME; Garbaccio RM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Rickert K; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo L; Prueksaritanont T; Li C; Mahan EA; Fernandez-Metzler C; Salata JJ; Hartman GD Bioorg Med Chem Lett; 2007 Oct; 17(19):5390-5. PubMed ID: 17761419 [TBL] [Abstract][Full Text] [Related]
3. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485 [TBL] [Abstract][Full Text] [Related]
4. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors. Nagarajan S; Skoufias DA; Kozielski F; Pae AN J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208 [TBL] [Abstract][Full Text] [Related]
5. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Zhang Y; Xu W Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830 [TBL] [Abstract][Full Text] [Related]
6. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs. Cox CD; Garbaccio RM Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439 [TBL] [Abstract][Full Text] [Related]
7. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877 [TBL] [Abstract][Full Text] [Related]
8. Target driven preclinical screening for new antimitotic chemotherapy agents. Novío S; Freire-Garabal M; Núñez MJ Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356 [TBL] [Abstract][Full Text] [Related]
9. New chemical tools for investigating human mitotic kinesin Eg5. Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors. Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776 [TBL] [Abstract][Full Text] [Related]
11. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Roecker AJ; Coleman PJ; Mercer SP; Schreier JD; Buser CA; Walsh ES; Hamilton K; Lobell RB; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo LC; Li C; Fernandez-Metzler C; Mahan EA; Prueksaritanont T; Hartman GD Bioorg Med Chem Lett; 2007 Oct; 17(20):5677-82. PubMed ID: 17766111 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors. Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341 [TBL] [Abstract][Full Text] [Related]
13. Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein. Muthuraja P; Himesh M; Prakash S; Venkatasubramanian U; Manisankar P Eur J Med Chem; 2018 Mar; 148():106-115. PubMed ID: 29454915 [TBL] [Abstract][Full Text] [Related]
14. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913 [TBL] [Abstract][Full Text] [Related]
15. Multicomponent reactions in antimitotic drug discovery. Cores A; Carbajales C; Coelho A Curr Top Med Chem; 2014; 14(20):2209-30. PubMed ID: 25440494 [TBL] [Abstract][Full Text] [Related]
16. Recent progress in discovery and development of antimitotic agents. Kiselyov A; Balakin KV; Tkachenko SE; Savchuk N; Ivachtchenko AV Anticancer Agents Med Chem; 2007 Mar; 7(2):189-208. PubMed ID: 17348827 [TBL] [Abstract][Full Text] [Related]
17. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update. Chamariya R; Suvarna V Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel EG5 inhibitors. Sarli V; Huemmer S; Sunder-Plassmann N; Mayer TU; Giannis A Chembiochem; 2005 Nov; 6(11):2005-13. PubMed ID: 16216042 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents. Gangjee A; Zhao Y; Hamel E; Westbrook C; Mooberry SL J Med Chem; 2011 Sep; 54(17):6151-5. PubMed ID: 21786793 [TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents. Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]